Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma

UNC Libraries(2020)10.17615/sn0d-vv38Source: DataRank Database

Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma is a research paper published in UNC Libraries (2020). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access0 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)OA: goldTopics (32)IDs (PubMed)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (28)

Maurilio Ponzoni ORCID,Kristy L. Richards ORCID,Andrés J.M. Ferreri ORCID,Jane N. Winter ORCID,Alexandar Tzankov ORCID

Live enrichment

PubMed:26573234

National Institutes of Health

Grant: 5P50CA142509-04

BIOSTATISTICS AND BIOINFORMATICS CORE

National Institutes of Health

Grant: 5P50CA136411-02

Epigenetic-based therapy of Hodgkin lymphoma

National Institutes of Health

Grant: 5R01CA187415-02

MYC as a Biomarker in Aggressive Non-Hodgkin Lymphoma

National Institutes of Health

Grant: 1R01CA138688-01A1

Convergence of MicroRNAs and p53 Signaling in Multiple Myeloma: Environmental Co

goldLicense: CC BY

https://doi.org/10.18632/oncotarget.6262

http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=6262&path%5B%5D=16221

https://dx.doi.org/10.17615/sn0d-vv38

https://pubmed.ncbi.nlm.nih.gov/26573234

http://dx.doi.org/10.18632/oncotarget.6262

Fields of Study

03 medical and health sciences0302 clinical medicine

Keywords

AdultMaleBCL2AdolescentBCL6diffuse large B-cell lymphomaAntineoplastic AgentsMYCDisease-Free SurvivalTranslocation, GeneticProto-Oncogene Proteins c-mycYoung AdultRadboudumc 2: Cancer development and immune defence RIMLS: Radboud Institute for Molecular Life SciencesBCL2; BCL6; MYC; diffuse large B-cell lymphoma; double-hit; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-bcl-6; Proto-Oncogene Proteins c-myc; Rituximab; Translocation, Genetic; Vincristine; Young AdultAntineoplastic Combined Chemotherapy ProtocolsHumansCyclophosphamideAgedAged, 80 and overMiddle AgedProto-Oncogene Proteins c-bcl-2double-hitVincristineDoxorubicinProto-Oncogene Proteins c-bcl-6PrednisoneFemaleLymphoma, Large B-Cell, DiffuseRituximabResearch Paper

Sustainable Development Goals

SDG 3: 3. Good health